Haemonetics Corporation is a global healthcare company that specializes in providing innovative blood management solutions
The company develops and manufactures a range of systems and products designed to optimize the collection, processing, and transfusion of blood and its components. Haemonetics focuses on enhancing blood safety and efficiency within healthcare settings, offering technologies that support blood donation and transfusion processes, as well as promoting the overall health of patients through effective blood management practices. Their commitment to improving patient outcomes and supporting healthcare providers makes them a key player in the field of healthcare technology.
HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price.
Blood products company Haemonetics (NYSEHAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was 1.7% above analysts’ consensus estimates.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112.
